Physician profile
John C Behrend
NPI 1104043769
$2,852.11
in general payments reported to CMS, 2019-2025
21 companies · $635 in 2025
The $635 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $330 · 2023: $535 · 2024: $733 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,902.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,902.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $264.95 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $248.13 | 2022-2025 | Livtencity |
| E.R. Squibb & Sons, L.L.C. | $241.96 | 2021 | |
| Novo Nordisk INC | $241.62 | 2024 | Wegovy |
| Alexion Pharmaceuticals, INC. | $226.13 | 2023-2024 | Ultomiris |
| Inari Medical, INC. | $159.56 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Veloxis Pharmaceuticals, INC. | $136.12 | 2023-2025 | Envarsus |
| Teva Pharmaceuticals USA, INC. | $131.58 | 2021 | |
| Sumitomo Pharma America, INC. | $123.62 | 2024 | Myfembree |
| Intercept Pharmaceuticals, INC. | $121.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.51 | 2025 | |
| Coloplast Corp | $113.83 | 2024 | |
| Gilead Sciences, INC. | $112.94 | 2024 | Epclusa |
| Abbvie INC. | $112.75 | 2025 | |
| Axsome Therapeutics, INC. | $104.06 | 2023 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $88.98 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.20 | 2025 | Xifaxan |
| Sk Life Science, INC. | $85.30 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $73.00 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $37.10 | 2021 | |
| Celgene Corporation | $26.27 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Behrend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.